Mar. 13 at 4:01 AM
$MAIA The 2028 patent cliff poses a
$170-350B revenue risk for Big Pharma through 2032, with oncology heavyweights like Merck's Keytruda (
$30B annual sales) losing U.S. exclusivity, enabling biosimilars and generics to erode markets—driving urgent M&A (e.g.,
$173B in at-risk sales by 2032) for innovative assets like MAIA Biotechnology (
$MAIA) THIO to fill gaps in immuno-oncology pipelines.
THIO's differentiated mechanism, high Phase 3 success probability (96-99% Bayesian), and pan-cancer appeal make it a prime partnership/acquisition target for firms like Merck (
$MRK), Bristol Myers Squibb (
$BMY), or Pfizer (
$PFE) seeking post-cliff growth in a
$668B oncology market by 2034.
More Information at MAIA Unofficial Reddit Community
https://www.reddit.com/r/MAIABiotech/comments/1rscru9/2028_patent_cliff_for_big_pharma/